

Hero MotoCorp

13 August 2021

All eyes on festive season

RESULT UPDATE

Sector: Auto	Rating: BUY
CMP: Rs 2,787	Target Price: Rs 3,465

Stock Info

Sensex/Nifty	54,225 / 16,182
Bloomberg	HMCL IN
Equity shares (mn)	200
52-wk High/Low	Rs 3,628/2,703
Face value	Rs 2
M-Cap (Rs bn)/(USD bn)	Rs 551bn/USD 7.4bn
3-m Avg volume	USD 22mn


Financial Snapshot (Rs mn)

Y/E Mar	FY21	FY22E	FY23E
Volume growth (%)	-10	6	12
Net Sales	308,006	343,623	386,481
EBIDTA	40,192	41,994	50,106
PAT	29,642	31,753	38,239
EPS (Rs)	148	159	191
PE (x)	18.8	17.5	14.5
EV/EBIDTA (x)	11.5	10.8	8.8
RoE (%)	20	20	22
RoCE (%)	26	26	28
FCF yield	6.6	3.7	5.5
Dividend yield (%)	3.8	3.2	3.6

Shareholding Pattern (%)

	Jun'21	Mar'21	Dec'20
Promoter	34.8	34.8	34.8
-Pledged	-	-	-
FII	35.0	37.2	35.9
DII	20.2	18.7	20.0
Others	10.0	9.3	9.3

Stock Performance (1-year)



Ronak Sarda

ronaksarda@systematixgroup.in
+91 22 6704 8059

Poorvi Banka

poorvibanka@systematixgroup.in
+91 22 6704 8063

Hero MotoCorp (Hero)'s 1QFY22 EBITDA margin of 9.4% was below consensus and our estimates as gross margin contraction hurt profitability. Strict cost controls have partially offset the impact of sharp raw material inflation. The management indicated that **domestic demand** was impacted due to local lockdowns, but is showing signs of improvement ahead of the festive season. Normal monsoon and healthy reservoir levels should also drive rural demand in the festive season. Hero has lost the market share it gained last year (~300bps) owing to weak demand, particularly in the executive segment. For EVs, Hero has a three-pronged strategy of (1) investment in Ather – the company has a premium scooter offering, (2) launching an in-house developed mass-market, fast charging EV in Mar'22 and (3) swappable battery solution through the JV with Gogoro later in CY22. We cut our FY22/23E EBITDA by 16%/13% to factor in the weak 1Q performance and maintain our BUY rating with a target price of Rs 3,465. We see value at the CMP as the company is on course to deliver a 5% FCF yield with 20% RoE in FY23. A sharp improvement in 2W demand and quicker-than-expected launches in the EV space can drive re-rating.

Key concall takeaways:

- Demand scenario and outlook:** Demand has picked up with the lifting of lockdowns and retail sales have reached ~80% of the pre-COVID levels. The management highlighted that festive occasions like Rath Yatra (in Gujarat/Orissa) and Eid saw an uptick of ~40% in sales. It expects these positive trends to continue through the festive season and 2HFY22. The company remains optimistic about the medium-term demand outlook on the back of positive underlying macro factors.
- RM cost headwinds and LEAP 2.0 cost savings:** Given the consistent increase in raw material costs, the company took an average price hike of 1% in 1QFY22 (in Apr'21) and 1-1.5% in 2QFY22 (in Jul'21). The management believes that price hikes along with LEAP cost savings should offset RM inflation. It expects RM costs to stabilise by 3Q, leading to an improvement in margins.
- Financing:** Retail financing penetration for Hero stood at 41% in 1Q vs. 48% QoQ; of this, its in-house financing arm, Hero Fincorp, contributed 40% (flat QoQ). The management expects financing to normalize gradually to ~50% by the festive season.
- EV segment plans:** Hero has a three-pronged EV strategy which includes mass-market, in-house products (being developed at its Germany & Jaipur R&D facilities), investment in Ather Energy and tie-up with Gogoro, Taiwan ([see our detailed note on EVs](#)). The management highlighted that its EV products are based on a fixed charging solution while the tie-up with Gogoro will provide swapping solutions along with swapping infrastructure, thus providing multiple charging options to buyers. The company plans to launch its first in-house electric 2W by Mar'22 with a fast-charging option.
- Spare parts sales:** Spare parts sales for the quarter stood at Rs 4.6bn (-57% QoQ), forming ~8% of sales against 12% of sales QoQ due to lockdown-led reduced mobility. Hero has increased its focus on the spare parts business by adopting a micro-distribution strategy (15% increase in retailers, direct connects with mechanics, etc.). The management expects spare parts to form ~10% of sales sustainably going forward.
- Capex:** Management has guided for a capex of Rs 7.5-10bn per annum over FY22-23E.

Outlook and valuation: We estimate volume/revenue/EBITDA/APAT CAGRs of 9%/12%/12%/14% between FY21-23E and see upside risks to our estimates. At the CMP, the stock trades at 14.5x PER and 8.8x EV/EBITDA on FY23E.

Investors are advised to refer disclosures made at the end of the research report.

Exhibit 1: Reported numbers vs. expectations

Rs mn	Reported	Est	Var %	Consensus	Var %
Net Sales	54,871	57,875	(5.2)	58,474	(6.2)
EBITDA	5,148	6,382	(19.3)	6,166	(16.5)
EBITDA Margin (%)	9.4	11.0	(164)	10.5	(116)
Adj PAT	3,654	4,975	(26.5)	4,637	(16.5)
Adj EPS	18.3	24.9	(26.5)	23.2	(21.2)

Source: Company, Systematix Institutional Research

Exhibit 2: Quarterly performance


Standalone (Rs mn)	1QFY21	2QFY21	3QFY21	4QFY21	1QFY22	YoY (%)	QoQ (%)
Net sales	29,715	93,673	97,758	86,860	54,871	84.7	(36.8)
- Raw material	20,939	66,600	68,912	61,173	39,796	90.1	(34.9)
(% of net sales)	70.5	71.1	70.5	70.4	72.5	206	210
- Staff expenditure	3,824	5,112	5,167	4,884	4,357	13.9	(10.8)
(% of net sales)	12.9	5.5	5.3	5.6	7.9	(493)	232
- Other expenditure	3,872	9,097	9,543	8,691	5,570	43.8	(35.9)
(% of net sales)	13.0	9.7	9.8	10.0	10.2	(288)	14
Total expenditure	28,635	80,809	83,621	74,748	49,722	73.6	(33.5)
EBITDA	1,081	12,864	14,136	12,112	5,148	376.5	(57.5)
EBITDA Margin (%)	3.6	13.7	14.5	13.9	9.4	575	(456)
Depreciation	1,708	1,732	1,698	1,631	1,630	(4.6)	(0.1)
EBIT	-627	11,133	12,438	10,480	3,519	(661.1)	(66.4)
Interest	63	46	47	63	61	(2.7)	(3.2)
Other Income	1,485	1,413	2,027	874	1,386	(6.6)	58.6
PBT	795	12,500	14,418	11,291	4,844	509.3	(57.1)
Tax	182	2,965	3,574	2,642	1,189	554.1	(55.0)
Reported PAT	613	9,534	10,845	8,650	3,654	496.1	(57.8)
Adjusted PAT	613	9,534	10,845	8,650	3,654	496.1	(57.8)
Adjusted EPS (Rs)	3.1	47.7	54.3	43.3	18.3	496.1	(57.8)
Total volumes (Nos)	563,426	1,820,278	1,845,274	1,568,313	1,024,489	81.8	(34.7)
Net realisation (Rs)	52,741	51,461	52,977	55,384	53,559	1.6	(3.3)
EBITDA / vehicle (Rs)	1,918	7,067	7,661	7,723	5,025	162.0	(34.9)

Source: Company, Systematix Institutional Research


Exhibit 3: Volume mix

Volume mix	1QFY21	2QFY21	3QFY21	4QFY21	1QFY22	YoY (%)	QoQ (%)
Motorcycles	525,503	1,689,866	1,689,034	1,437,368	959,571	82.6	(33.2)
Scooters	37,923	130,412	156,240	130,945	64,918	71.2	(50.4)
Total Volumes	563,426	1,820,278	1,845,274	1,568,313	1,024,489	81.8	(34.7)
Exports out of above	27,639	41,770	53,147	71,764	83,800	203.2	16.8
Scooters as % of Total Volumes	6.7%	7.2%	8.5%	8.3%	6.3%	(39)	(201)
Export as % of Total Volumes	4.9%	2.3%	2.9%	4.6%	8.2%	327	360


Source: Company, Systematix Institutional Research

Exhibit 4: Price hikes for Hero HF Deluxe


Source: Company, Systematix Institutional Research

Exhibit 5: Price hikes for Hero Splendor


Source: Company, Systematix Institutional Research

Exhibit 6: Revenue and YoY growth trend


Source: Company, Systematix Institutional Research

Exhibit 7: Gross margin/EBITDA margin trend


Source: Company, Systematix Institutional Research

Exhibit 8: Quarterly volume trend


Source: Company, Systematix Institutional Research

Exhibit 9: Quarterly EBITDA margin trend

Source: Company, Systematix Institutional Research

Exhibit 10: Annual revenue and YoY growth (RHS)

Source: Company, Systematix Institutional Research

Exhibit 11: Annual EBITDA and EBITDA margins (RHS)

Source: Company, Systematix Institutional Research

Exhibit 12: Annual segment-wise volume trend

Volume (units)	FY15	FY16	FY17	FY18	FY19	FY20	FY21	FY22E	FY23E
Domestic Motorcycles	5,679,634	5,603,136	5,693,681	6,499,051	6,893,688	5,828,782	5,157,415	5,363,712	6,001,993
YoY growth %	5%	-1%	2%	14%	6%	-15%	-12%	4%	12%
Domestic Scooters	752,052	818,777	789,974	883,667	719,087	402,676	443,458	478,935	536,407
YoY growth %	9%	9%	-4%	12%	-19%	-44%	10%	8%	12%
Exports	200,017	210,239	180,391	204,475	208,056	178,261	190,823	303,862	340,325
YoY growth %	53%	5%	-14%	13%	2%	-14%	7%	59%	12%
Total volume	6,631,703	6,632,152	6,664,046	7,587,193	7,820,831	6,409,719	5,791,696	6,146,508	6,878,725
YoY growth %	6%	0%	0%	14%	3%	-18%	-10%	6%	12%

Source: SIAM, Company, Systematix Institutional Research

FINANCIALS (STANDALONE)

Profit & Loss Statement

YE: Mar (Rs mn)	FY19	FY20	FY21	FY22E	FY23E
Net sales	336,505	288,361	308,006	343,623	386,481
Growth, %	4	(14)	7	12	12
RM expenses	-233,177	-196,974	-217,623	-248,440	-274,402
Employee expenses	-17,302	-18,417	-18,987	-18,899	-20,870
Other expenses	-36,725	-33,390	-31,203	-34,291	-41,104
EBITDA	49,301	39,580	40,192	41,994	50,106
Growth, %	(7)	(20)	2	4	19
Margin, %	14.7	13.7	13.0	12.2	13.0
Depreciation	-6,020	-8,180	-6,769	-6,952	-7,364
EBIT	43,281	31,400	33,424	35,042	42,742
Growth, %	(8)	(27)	6	5	22
Margin, %	12.9	10.9	10.9	10.2	11.1
Interest paid	-86	-220	-218	-218	-218
Other Income	6,913	7,783	5,799	6,958	7,793
Non-recurring Items	0	6,774	0	0	0
Pre-tax profit	50,108	38,963	39,004	41,781	50,316
Tax provided	-16,258	-9,404	-9,362	-10,028	-12,077
Profit after tax	33,849	29,559	29,642	31,753	38,239
Others (Minorities, Associates)	-	-	-	-	-
Net Profit	33,849	36,333	29,642	31,753	38,239
Growth, %	(8)	7	(18)	7	20
Net Profit (adjusted)	33,849	29,559	29,642	31,753	38,239

Source: Company, Systematix Institutional Research;

Balance Sheet

YE: Mar (Rs mn)	FY19	FY20	FY21	FY22E	FY23E
Cash & bank	1,360	2,419	2,572	1,379	8,144
Marketable securities cost	50,517	72,141	91,230	99,251	107,877
Debtors	28,216	16,031	24,268	18,829	21,177
Inventory	10,724	10,920	14,696	9,414	10,589
Loans & advances	850	896	892	1,018	1,124
Other current assets	23,971	10,417	9,938	10,931	12,024
Total current assets	65,121	40,683	52,364	41,571	53,059
Investments	9,169	10,086	13,767	16,245	19,169
Gross fixed assets	119,079	142,244	147,726	155,726	165,726
Less: Depreciation	-72,893	-81,073	-87,841	-94,793	-102,158
Add: Capital WIP	5,419	3,413	4,366	4,366	4,366
Net fixed assets	46,186	61,171	59,884	60,932	63,568
Total assets	176,411	187,493	221,611	222,365	248,038
Current liabilities	40,713	39,512	62,257	52,071	57,462
Provisions	1,762	2,689	3,328	498	2,521
Total current liabilities	42,475	42,201	65,585	52,569	59,983
Non-current liabilities	5,365	3,928	4,041	4,041	4,041
Total liabilities	47,840	46,129	69,626	56,610	64,024
Paid-up capital	399	400	400	400	400
Reserves & surplus	128,172	140,965	151,585	165,356	183,615
Shareholders' equity	128,571	141,364	151,984	165,755	184,015
Total equity & liabilities	176,411	187,493	221,611	222,365	248,038

Source: Company, Systematix Institutional Research

Cash Flow

YE: Mar (Rs mn)	FY19	FY20	FY21	FY22E	FY23E
Pre-tax profit	50,108	45,737	39,004	41,781	50,316
Depreciation	6,020	8,180	6,769	6,952	7,364
Chg in working capital	-24,871	25,222	11,857	-3,416	2,692
Total tax paid	-16,010	-10,841	-9,249	-10,028	-12,077
CFO	7,527	54,101	41,727	28,549	40,721
Capital expenditure	-7,895	-13,586	-5,146	-8,000	-10,000
Chg in investments	-556	-556	-555	-555	-555
Chg in marketable securities	16,122	-21,984	-22,215	-9,945	-10,994
CFI	14,706	-28,831	-22,099	-11,541	-13,756
Free cash flow	-925	39,959	36,026	19,994	30,166
Debt raised/(repaid)	0	0	0	0	0
Dividend (incl. tax)	-22,197	-23,991	-19,257	-17,982	-19,980
CFF	-22,283	-24,211	-19,475	-18,200	-20,198
Net chg in cash	(50)	1,059	153	(1,193)	6,766
Opening cash balance	1,410	1,360	2,419	2,572	1,379
Closing cash balance	1,360	2,419	2,572	1,379	8,144

Source: Company, Systematix Institutional Research

Ratios

YE: Mar	FY19	FY20	FY21	FY22E	FY23E
EPS (INR)	170	148	148	159	191
PER (x)	16.4	18.8	18.8	17.5	14.5
Price/Book (x)	4.3	3.9	3.7	3.4	3.0
EV/EBITDA (x)	10.2	12.2	11.5	10.8	8.8
EV/Net sales (x)	1.5	1.7	1.5	1.3	1.1
RoE (%)	27	22	20	20	22
RoCE (%)	39	28	26	26	28
Fixed Asset turnover (x)	2.8	2.0	2.1	2.2	2.3
Dividend Yield (%)	3.4	3.2	3.8	3.2	3.6
Receivable (days)	31	20	29	20	20
Inventory (days)	14	16	20	11	11
Payable (days)	43	44	71	49	49
Revenue Growth (%)	4	(14)	7	12	12
EBIDTA Growth (%)	(7)	(20)	2	4	19
EPS Growth, %	(8)	(13)	0	7	20
Net D/E ratio (x)	(0.4)	(0.6)	(0.6)	(0.6)	(0.6)

Source: Company, Systematix Institutional Research

Institutional Equities Team

Nikhil Khandelwal	Managing Director	+91-22-6704 8001	nikhil@systematixgroup.in
Navin Roy Vallabhaneni	President & Head – IE & ECM	+91-22-6704 8065	navin@systematixgroup.in
Equity Research			
Analysts	Industry Sectors	Desk-Phone	E-mail
Rahul Jain	Metals & Mining	+91-22-6704 8066	rahuljain@systematixgroup.in
Ronak Sarda	Auto, Auto Ancillaries	+91-22-6704 8059	ronaksarda@systematixgroup.in
Rakesh Kumar	Banking, Insurance	+91-22-6704 8041	rakeshkumar@systematixgroup.in
Praful Bohra	Pharmaceuticals and Healthcare	+91-22-6704 8064	prafulbohra@systematixgroup.in
Shubhranshu Mishra	NBFCs & Diversified Financials	+91-22-6704 8024	shubhranshumishra@systematixgroup.in
Sanjeev Kumar Singh	Cement, Building Materials, Paints	+91-22-6704 8017	sanjeevsingh@systematixgroup.in
Premal Kamdar	Consumer Staples	+91-22-6704 8090	premalkamdar@systematixgroup.in
Amar Kedia	Infra, Cap Goods, Logistics, Consumer Durables	+91-22-6704 8084	amaruedia@systematixgroup.in
Ashutosh Joytiraditya	Consumer, Retail	+91-22-6704 8068	ashutoshj@systematixgroup.in
Naushad Chaudhary	Chemicals, Textiles, Building Materials, Midcaps	+91-22-6704 8036	naushadchaudhary@systematixgroup.in
Harsh Mittal	Cement, Building Materials, Paints	+91-22-6704 8098	harshmittal@systematixgroup.in
Poorvi Banka	Auto, Auto Ancillaries	+91-22-6704 8063	poorvibanka@systematixgroup.in
Nikhil Shah	Banking, Insurance	+91-22-6704 8091	nikhilshah@systematixgroup.in
Tausif Shaikh	Pharmaceuticals and Healthcare	+91-22-6704 8046	tausifshaikh@systematixgroup.in
Shweta Dikshit	Metals & Mining	+91-22-6704 8042	shwetadikshit@systematixgroup.in
Shilpashree Venkatesh	Macro-Strategy	+91-22-6704 8078	shilpav@systematixgroup.in
Equity Sales & Trading			
Name		Desk-Phone	E-mail
Vipul Sanghvi	Director and Head - Sales	+91-22-6704 8062	vipulsanghvi@systematixgroup.in
Ashok Kumar Agarwal	Sales	+91-22-6704 8058	ashokagarwal@systematixgroup.in
Jigar Kamdar	Sales	+91-22-6704 8060	jigarkamdar@systematixgroup.in
Rahul Khandelwal	Sales	+91-22-6704 8033	rahul@systematixgroup.in
Pawan Sharma	Director and Head - Sales Trading	+91-22-6704 8067	pawansharma@systematixgroup.in
Mukesh Chaturvedi	Vice President and Co Head - Sales Trading	+91-22-6704 8074	mukeshchaturvedi@systematixgroup.in
Vinod Bhuwad	Sales Trading	+91-22-6704 8051	vinodbhuwad@systematixgroup.in
Rashmi Solanki	Sales Trading	+91-22-6704 8097	rashmisolanki@systematixgroup.in
Rahul Thakar	Sales Trading - Derivatives	+91-22-6704 8073	rahulthakar@systematixgroup.in
Vipul Chheda	Dealer	+91-22-6704 8050	vipulchheda@systematixgroup.in
Amit Sawant	Dealer	+91-22-6704 8054	amitsawant@systematixgroup.in
Paras Shah	Dealer	+91-22-6704 8047	parasshah@systematixgroup.in
Suketu Vyas	Dealer	+91-22-6704 8050	suketuvyas@systematixgroup.in
Corporate Access			
Audrey Leolyn Mendonca	Assistant Vice President	+91-22-6704 8088	audreymendonca@systematixgroup.in
Production			
Yukti Vidyarthi	Editor	+91-22-6704 8071	yukti@systematixgroup.in
Mrunali Pagdhare	Production	+91-22-6704 8057	mrunalip@systematixgroup.in
Vijayendra Achrekar	Production	+91-22-6704 8089	vijayendraachrekar@systematixgroup.in
Operations			
Sachin Malusare	Vice President	+91-22-6704 8055	sachinmalusare@systematixgroup.in
Sugandha Rane	Assistant Vice President	+91-22-6704 8056	sugandha@systematixgroup.in
Jignesh Mistry	Manager	+91-22-6704 8049	jigneshmistry@systematixgroup.in
Ravikiran Dasaka	Manager	+91-22-6704 8622	ravikiran@systematixgroup.in
Ravi Agarwal	Assistant Manager	+91-22-6704 8016	raviagarwal@systematixgroup.in

DISCLOSURES/APPENDIX

I. ANALYST CERTIFICATION

I, **Ronak Sarda, Poorvi Banka**; hereby certify that (1) views expressed in this research report accurately reflect my/our personal views about any or all of the subject securities or issuers referred to in this research report, (2) no part of my/our compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this research report by **Systematix Shares and Stocks (India) Limited (SSSIL)** or its group/associate companies, (3) reasonable care is taken to achieve and maintain independence and objectivity in making any recommendations.

Disclosure of Interest Statement	Update
Analyst holding in the stock	No
Served as an officer, director or employee	No

II. ISSUER SPECIFIC REGULATORY DISCLOSURES, unless specifically mentioned in point no. 9 below:

1. The research analyst(s), SSSIL, associates or relatives do not have any financial interest in the company(ies) covered in this report.
2. The research analyst(s), SSSIL, associates or relatives collectively do not hold more than 1% of the securities of the company(ies) covered in this report as of the end of the month immediately preceding the distribution of the research report.
3. The research analyst(s), SSSIL, associates or relatives did not have any other material conflict of interest at the time of publication of this research report.
4. The research analyst, SSSIL and its associates have not received compensation for investment banking or merchant banking or brokerage services or any other products or services from the company(ies) covered in this report in the past twelve months.
5. The research analyst, SSSIL or its associates have not managed or co-managed a private or public offering of securities for the company(ies) covered in this report in the previous twelve months.
6. SSSIL or its associates have not received compensation or other benefits from the company(ies) covered in this report or from any third party in connection with this research report.
7. The research analyst has not served as an officer, director or employee of the company(ies) covered in this research report.
8. The research analyst and SSSIL have not been engaged in market making activity for the company(ies) covered in this research report.
9. Details of SSSIL, research analyst and its associates pertaining to the companies covered in this research report:

Sr. No.	Particulars	Yes / No.
1	Whether compensation was received from the company(ies) covered in the research report in the past 12 months for investment banking transaction by SSSIL.	No
2	Whether research analyst, SSSIL or its associates and relatives collectively hold more than 1% of the company(ies) covered in the research report.	No
3	Whether compensation has been received by SSSIL or its associates from the company(ies) covered in the research report.	No
4	Whether SSSIL or its affiliates have managed or co-managed a private or public offering of securities for the company(ies) covered in the research report in the previous twelve months.	No
5	Whether research analyst, SSSIL or associates have received compensation for investment banking or merchant banking or brokerage services or any other products or services from the company(ies) covered in the research report in the last twelve months.	No

10. There is no material disciplinary action taken by any regulatory authority that impacts the equity research analysis activities.

STOCK RATINGS

BUY (B): The stock's total return is expected to exceed 15% over the next 12 months.

HOLD (H): The stock's total return is expected to be within -15% to +15% over the next 12 months.

SELL (S): The stock's total return is expected to give negative returns of more than 15% over the next 12 months.

NOT RATED (NR): The analyst has no recommendation on the stock under review.

INDUSTRY VIEWS

ATTRACTIVE (AT): Fundamentals/valuations of the sector are expected to be attractive over the next 12-18 months.

NEUTRAL (NL): Fundamentals/valuations of the sector are expected to neither improve nor deteriorate over the next 12-18 months.

CAUTIOUS (CS): Fundamentals/valuations of the sector are expected to deteriorate over the next 12-18 months.

III. DISCLAIMER

The information and opinions contained herein have been compiled or arrived at based on the information obtained in good faith from sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy completeness or correctness.

This document is for information purposes only. This report is based on information that we consider reliable; we do not represent that it is accurate or complete and one should exercise due caution while acting on it. Description of any company(ies) or its/their securities mentioned herein are not complete and this document is not and should not be construed as an offer or solicitation of an offer to buy or sell any securities or other financial instruments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. All opinions, projections and estimates constitute the judgment of the author as on the date of the report and these, plus any other information contained in the report, are subject to change without notice. Prices and availability of financial instruments are also subject to change without notice. This report is intended for distribution to institutional investors.

This report is not directed to or intended for display, downloading, printing, reproducing or for distribution to or use by, any person or entity that is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject to SSSIL or its affiliates to any registration or licensing requirement within such jurisdiction. If this report is inadvertently sent or has reached any individual in such country, especially USA, the same may be ignored and brought to the attention of the sender. Neither this document nor any copy of it may be taken or transmitted into the United States (to U.S. persons), Canada, or Japan or distributed, directly or indirectly, in the United States or Canada or distributed or redistributed in Japan or to any resident thereof. Any unauthorized use, duplication,

redistribution or disclosure of this report including, but not limited to, redistribution by electronic mail, posting of the report on a website or page, and/or providing to a third party a link, is prohibited by law and will result in prosecution. The information contained in the report is intended solely for the recipient and may not be further distributed by the recipient to any third party.

SSSL generally prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, SSSL generally prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that they cover. Our salespeople, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein. Our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. The views expressed in this research report reflect the personal views of the analyst(s) about the subject securities or issues and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report. The compensation of the analyst who prepared this document is determined exclusively by SSSL; however, compensation may relate to the revenues of the Systematix Group as a whole, of which investment banking, sales and trading are a part. Research analysts and sales persons of SSSL may provide important inputs to its affiliated company(ies).

Foreign currencies denominated securities, wherever mentioned, are subject to exchange rate fluctuations which could have an adverse effect on their value or price or the income derived from them. In addition, investors in securities such as ADRs, the values of which are influenced by foreign currencies, effectively assume currency risk. SSSL, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on the basis of this report including but not restricted to fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc.

SSSL and its affiliates, officers, directors, and employees subject to the information given in the disclosures may: (a) from time to time, have long or short positions in, and buy or sell, the securities thereof, of company (ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation (financial interest) or act as a market maker in the financial instruments of the company (ies) discussed herein or act as advisor or lender / borrower to such company (ies) or have other potential material conflict of interest with respect to any recommendation and related information and opinions. The views expressed are those of the analyst and the company may or may not subscribe to the views expressed therein.

SSSL, its affiliates and any third party involved in, or related to, computing or compiling the information hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of this information. Without limiting any of the foregoing, in no event shall SSSL, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind. The company accepts no liability whatsoever for the actions of third parties. The report may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the report refers to website material of the company, the company has not reviewed the linked site. Accessing such website or following such link through the report or the website of the company shall be at your own risk and the company shall have no liability arising out of, or in connection with, any such referenced website.

SSSL will not be liable for any delay or any other interruption which may occur in presenting the data due to any technical glitch to present the data. In no event shall SSSL be liable for any damages, including without limitation, direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by SSSL through this presentation.

SSSL or any of its other group companies or associates will not be responsible for any decisions taken on the basis of this report. Investors are advised to consult their investment and tax consultants before taking any investment decisions based on this report.



Systematix Shares and Stocks (India) Limited:

Registered and Corporate address: The Capital, A-wing, No. 603 – 606, 6th Floor, Plot No. C-70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051
 CIN - U65993MH1995PLC268414 | BSE SEBI Reg. No.: INZ000171134 (Member Code: 182) | NSE SEBI Reg. No.: INZ000171134 (Member Code: 11327) | MCX SEBI Reg. No.: INZ000171134 (Member Code: 56625) | NCDEX SEBI Reg. No.: INZ000171134 (Member Code: 1281) | Depository Participant SEBI Reg. No.: IN-DP-480-2020 (DP Id: 34600) | PMS SEBI Reg. No.: INP000002692 | Research Analyst SEBI Reg. No.: INH200000840 | Investment Advisor SEBI Reg. No. INA000010414 | AMFI : ARN - 64917